Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Klarna CEO and Sutter Hill take victory lap after Jony Ive’s OpenAI deal

From TechCrunch

By Julie Bort

May 22, 2025

Klarna CEO and Sutter Hill take victory lap after Jony Ive’s OpenAI deal

Klarna CEO and Sutter Hill take victory lap after Jony Ive’s OpenAI deal

Hours after Sam Altman and Jony Ive announced on Wednesday that OpenAI was buying Ive’s company, io, in an all-stock transaction valued at $6.5 billion, Klarna CEO Sebastian Siemiatkowski posted a surprising message on X. 

Siemiatkowski’s family investment office, Flat Capital, had bought shares in io six months earlier, he said. Since this is an all-stock deal, those io shares will be converted into shares in the for-profit arm of OpenAI.

“Excited that @FlatCapital was an investor in io and that we will now receive even more shares in OpenAI at a hefty return for an investment we did some 6 months ago,” Siemiatkowski tweeted. 

The post generated so much interest that his investment firm issued a public statement confirming that io was the mystery, unnamed company it backed when it announced its four investments in a “mini-portfolio” of U.S. AI companies. Flat Capital disclosed that it spent 34 million SEK on io, which converts to about $3.6 million.

Then came another surprising tweet from former Googler and designer Luke Wroblewski, who now works as a managing director at the secretive Silicon Valley VC powerhouse firm Sutter Hill Ventures. 

In a since-deleted tweet and LinkedIn post, Wroblewski wrote, “congrats to io on the $6.5B acquisition by OpenAI today. happy to have been investors in this one.”

According to some who saw additional now-deleted tweets about Sutter’s investment, the firm may have been the second largest investor in io. TechCrunch couldn’t confirm that, though. Sutter didn’t respond to our request for comment, and Wroblewski deleted his posts after we reached out. 

The biggest investor in io was OpenAI itself, with a 23% stake, sources told Bloomberg, adding that this stake was valued at around $1.5 billion. That means OpenAI paid about $5 billion in stock for the remaining shares. Other io backers, Bloomberg reported, included Laurene Powell Jobs’ firm Emerson Collective, Thrive Capital, Maverick Ventures, SV Angel, and the OpenAI Fund. As we previously reported, that fund isn’t backed with the AI model maker’s money but by outside investors. Despite the deleted tweets, Bloomberg also confirmed Sutter Hill Ventures was an investor.

View original article on techcrunch.com

Most Recent

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.

Jul 15, 2026

David Beckham’s health drink startup IM8 takes $1B from General Catalyst’s unusual CVF fund

David Beckham’s health drink startup IM8 takes $1B from General Catalyst’s unusual CVF fund

General Catalyst’s Customer Value Fund doesn't make equity investments. It's providing $1 billion for IM8, known for its longevity vitamin drink.

Jul 14, 2026

Reed Jobs would rather talk about curing cancer than his last name

Reed Jobs would rather talk about curing cancer than his last name

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs' words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.

Jul 11, 2026

Similar Posts

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.

Jul 15, 2026

David Beckham’s health drink startup IM8 takes $1B from General Catalyst’s unusual CVF fund

David Beckham’s health drink startup IM8 takes $1B from General Catalyst’s unusual CVF fund

General Catalyst’s Customer Value Fund doesn't make equity investments. It's providing $1 billion for IM8, known for its longevity vitamin drink.

Jul 14, 2026

Reed Jobs would rather talk about curing cancer than his last name

Reed Jobs would rather talk about curing cancer than his last name

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs' words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.

Jul 11, 2026

Most Recent

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.

Jul 15, 2026

David Beckham’s health drink startup IM8 takes $1B from General Catalyst’s unusual CVF fund

David Beckham’s health drink startup IM8 takes $1B from General Catalyst’s unusual CVF fund

General Catalyst’s Customer Value Fund doesn't make equity investments. It's providing $1 billion for IM8, known for its longevity vitamin drink.

Jul 14, 2026

Reed Jobs would rather talk about curing cancer than his last name

Reed Jobs would rather talk about curing cancer than his last name

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs' words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.

Jul 11, 2026

Similar Posts

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Daniel Ek’s body-scanning startup Neko Health raises another $700M

Neko Health has developed proprietary body-scanning technology, which it couples with bloodwork, to assess a person's health.

Jul 15, 2026

David Beckham’s health drink startup IM8 takes $1B from General Catalyst’s unusual CVF fund

David Beckham’s health drink startup IM8 takes $1B from General Catalyst’s unusual CVF fund

General Catalyst’s Customer Value Fund doesn't make equity investments. It's providing $1 billion for IM8, known for its longevity vitamin drink.

Jul 14, 2026

Reed Jobs would rather talk about curing cancer than his last name

Reed Jobs would rather talk about curing cancer than his last name

When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs' words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.

Jul 11, 2026